Table 3.
Univariate analysis on local recurrence (LR) rate among various patient groups
| Factor | Group | Number of LR | LR rate (%) | P |
|---|---|---|---|---|
| Age | <22 | 4/23 | 17.4 | 0.959 |
| ≥22 | 4/24 | 16.7 | ||
| Gender | Male | 4/28 | 14.3 | 0.516 |
| Female | 4/19 | 21.1 | ||
| Tumour site | Extremities | 5/41 | 12.2 | 0.020a |
| Trunk | 3/6 | 50 | ||
| MSTS stage | IIB | 7/40 | 17.5 | 0.908 |
| IIIB | 1/7 | 14.3 | ||
| Surgery type | Amputation | 2/6 | 33.3 | 0.216 |
| Resection | 6/41 | 14.6 | ||
| Pathological type | Osteoblastic | 6/38 | 15.8 | 0.69 |
| Other type | 2/9 | 22.2 | ||
| Tumour size | <8.2 | 2/22 | 9.1 | 0.295 |
| ≥8.2 | 5/24 | 20.8 | ||
| Histological response | Good | 1/12 | 8.3 | 0.335 |
| Poor | 7/35 | 20 | ||
| Margin status | Wide | 3/28 | 10.7 | 0.004a |
| Close | 1/12 | 8.3 | ||
| Positive | 4/7 | 57.1 | ||
| Chemo regimens | CDDP, ADRIA, MTX | 2/19 | 10.5 | 0.358 |
| Other regimens | 6/28 | 21.4 | ||
| Completed cycles of chemo | < 5 cycles | 3/12 | 25 | 0.222 |
| ≥ 5 cycles | 5/35 | 14.3 |
Chemo chemotherapy, CDDP cisplatin, ADRIA adriamycin, MTX methotrexate
a Statistically significant